Benzinga | Jul 7, 2021 09:33AM EDT

Citius Pharmaceuticals Says Mino-Lok NDA Submission Planned For 2022 Following Anticipated Completion Of Phase 3 Trial By End Of 2021 Or Early 2022

-SEC Filing